Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Estrone | Estrone may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Estradiol | Estradiol may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Mestranol | Mestranol may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Estriol | Estriol may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Tibolone | Tibolone may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Zeranol | Zeranol may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Equol | Equol may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Promestriene | Promestriene may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Formononetin | Formononetin may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Estetrol | Estetrol may increase the thrombogenic activities of Bevacizumab zirconium Zr-89. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Bevacizumab zirconium Zr-89. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bevacizumab zirconium Zr-89. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Bevacizumab zirconium Zr-89. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Bevacizumab zirconium Zr-89. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Bevacizumab zirconium Zr-89. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bevacizumab zirconium Zr-89. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bevacizumab zirconium Zr-89. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Bevacizumab zirconium Zr-89. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bevacizumab zirconium Zr-89. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Bevacizumab zirconium Zr-89. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Bevacizumab zirconium Zr-89. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Bevacizumab zirconium Zr-89. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bevacizumab zirconium Zr-89. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bevacizumab zirconium Zr-89. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Bevacizumab zirconium Zr-89. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bevacizumab zirconium Zr-89. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bevacizumab zirconium Zr-89. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Bevacizumab zirconium Zr-89. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bevacizumab zirconium Zr-89. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Bevacizumab zirconium Zr-89. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Bevacizumab zirconium Zr-89. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Bevacizumab zirconium Zr-89. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bevacizumab zirconium Zr-89. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bevacizumab zirconium Zr-89. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Bevacizumab zirconium Zr-89. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Bevacizumab zirconium Zr-89. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Bevacizumab zirconium Zr-89. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Bevacizumab zirconium Zr-89. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Bevacizumab zirconium Zr-89. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Bevacizumab zirconium Zr-89. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Bevacizumab zirconium Zr-89. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Bevacizumab zirconium Zr-89. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Bevacizumab zirconium Zr-89. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Bevacizumab zirconium Zr-89. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Bevacizumab zirconium Zr-89. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Bevacizumab zirconium Zr-89. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Bevacizumab zirconium Zr-89. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Bevacizumab zirconium Zr-89. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Bevacizumab zirconium Zr-89. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Bevacizumab zirconium Zr-89. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Bevacizumab zirconium Zr-89. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Bevacizumab zirconium Zr-89. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Bevacizumab zirconium Zr-89. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Bevacizumab zirconium Zr-89. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Bevacizumab zirconium Zr-89. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Bevacizumab zirconium Zr-89. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Bevacizumab zirconium Zr-89. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Bevacizumab zirconium Zr-89. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Bevacizumab zirconium Zr-89. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Bevacizumab zirconium Zr-89. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Bevacizumab zirconium Zr-89. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Bevacizumab zirconium Zr-89. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Bevacizumab zirconium Zr-89. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Bevacizumab zirconium Zr-89. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Bevacizumab zirconium Zr-89. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Bevacizumab zirconium Zr-89. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Bevacizumab zirconium Zr-89. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bevacizumab zirconium Zr-89. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Bevacizumab zirconium Zr-89. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Bevacizumab zirconium Zr-89. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Bevacizumab zirconium Zr-89. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Bevacizumab zirconium Zr-89. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Bevacizumab zirconium Zr-89. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Bevacizumab zirconium Zr-89. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Bevacizumab zirconium Zr-89. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Bevacizumab zirconium Zr-89. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Bevacizumab zirconium Zr-89. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Bevacizumab zirconium Zr-89. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Bevacizumab zirconium Zr-89. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Bevacizumab zirconium Zr-89. |